Navigation Links
Cerecor Announces Clearance of IND for FP01
Date:4/11/2012

BALTIMORE, April 11, 2012 /PRNewswire/ -- Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, today announced that its Investigational New Drug (IND) Application for FP01 for the treatment of cough has cleared the 30 day deliberation period by the U.S. Food and Drug Administration (FDA).  The Company plans to immediately characterize the pharmacokinetics of FP01 lozenges in humans and thereafter to initiate an exploratory Phase II acute cough study in healthy subjects with upper respiratory tract infections (URTI). 

(Logo: http://photos.prnewswire.com/prnh/20120411/PH85852LOGO )

"Acceptance by the FDA of this application and the advancement of FP01 to clinical testing are important milestones for the Company and key steps along the path to commercialize a treatment for acute and chronic cough. The data we plan to generate from the initial Phase II study will educate us about the effect size of FP01 as an antitussive, providing for future studies," said Dr. Blake Paterson, CEO and co-founder of Cerecor.

About Cerecor Inc.

Cerecor Inc. ("Cerecor" or the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. Cerecor is focused on translational medicine -- the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. Cerecor's product pipeline also includes preclinical drug development candidates in cognition and schizophrenia
'/>"/>

SOURCE Cerecor Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. China Botanic Announces Results of Annual General Meeting
2. iBio Announces Production of Biosimilar Palivizumab with its iBioLaunch™ Technology
3. SafeWire, LLC. Announces first US product launch of Y-wire™
4. Sunpeaks Ventures Announces Letter of Intent to Export Clotamin to Top Russian Pharmacies
5. Rapid Fire Marketing Announces the First Shipment of its Vapor Inhaler Model Named the CannaCig Has Passed All Patient Tests; Second Round of Production to Start This Week
6. Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores
7. Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2012 Results
8. BioNeutral Group Announces Positive Results for the Ygiene 206 Sterilization Tests
9. Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
10. BONESUPPORTS New CEO Announces 100 Day Plan
11. Sunpeaks Ventures Announces Agreement with Albeck Financial Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015 RadiologyAuction will have their ... video and product demonstrations at the end of the ... such as Kodak and Fuji Cr,s, Agfa and Sony, ... the first event. Various imaging equipment will be available ... After years of buying and selling imaging ...
(Date:5/4/2015)... May 4, 2015  Oncobiologics, Inc., a biotherapeutics ... (mAb) biosimilars, has completed the construction of its ... in Cranbury, New Jersey . ... facility is designed to utilize multiple technologies that ... scale.  Through the use of the latest single-use ...
(Date:5/4/2015)... Calif. , May 4, 2015  Isis Pharmaceuticals, ... exclusive license agreement with Bayer HealthCare (Bayer) to develop ... thrombosis. Under the terms of the agreement, Isis is ... payments, including an immediate $100 million up-front payment and ... following a Phase 2 study in patients with compromised ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5
(Date:5/4/2015)... Each year, the Susan G. Komen organization ... awareness for breast cancer. This year, Dr. Mark Deutsch and ... the entertainment sponsor for the 25th annual Susan G. Komen ... the Lenox Square Mall. , The Komen organization hopes have ... $1.2 million. Perimeter Plastic Surgery has not only taken on ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Getting patients ... manage their health is critical to achieving the “triple ... reducing costs, but this will require a shift in ... also demands that health systems move beyond their traditional ... took part in the third live meeting of the ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 “ LiveSchool ... monthly AppWatch, which takes a look at the latest ... and Windows. Joe Toohey, the host of AppWatch and ... viewers how this application allows teachers to reward students ... than some realize, especially in the classroom. And ...
(Date:5/4/2015)... The Lymphoma Research Foundation (LRF) – the ... lymphoma research and serving the lymphoma community through a ... services – is set to host its annual Ace ... Orange, NJ on June 1, 2015. Since 2010, the ... through LRF. , This year, the Lymphoma Research Foundation ...
(Date:5/4/2015)... The opportunity for children to dream of ... motivating forces behind The Fairy Godmother Next Door, a new ... L. Stark. , The inspiration for the enchanting story of ... from Stark’s desire to be a fairy godmother. , “My ... to my neighbors’ children since they were born. We discuss ...
Breaking Medicine News(10 mins):Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 4Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2
... 8, 2007 -- Results from two investigational Phase I ... preliminary anti-tumor activity in patients with relapsed and/or refractory ... 10 of 21 (48 percent) evaluable patients had a ... combination treatment. Data from a second study, sponsored ...
... Boca Raton, FL, December 8, 2007 Researchers may ... almost immediately by directly targeting novel molecules in the ... can lead to longer times for medication to take ... American College of Neuropsychopharmacology (ACNP) annual meeting. The antidepressant ...
... Elderly may be especially prone to depression this time of ... For some older people, the holidays can generate feelings of ... or health problems, experts note. , To help seniors ... offers the following tips: , Socialize. Ask family and ...
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced today that ... Company that it will evaluate the,approval of potential anti-arrhythmic ... ongoing review of the Company,s,supplemental new drug application (sNDA)., ... seeking expansion to the,approved product labeling for Ranexa to ...
... Legendary blues artists Bobby,Rush and James "Super Chikan" Johnson ... Blues Marathon and Half-Marathon on Saturday,January 5, 2008. The ... at 200,South Commerce Street, in downtown Jackson. Doors will ... on stage at 8:00 p.m., and the Bobby Rush,Revue ...
... Ala., Dec. 7 BioHorizons Implant Systems,Inc. ... to a,state-of-the- art, 44,000 square foot facility. ... houses all administrative services, a newly,formed manufacturing ... will include machining, surface treatment and packaging ...
Cached Medicine News:Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 3Health News:Study shows new strategy for developing antidepressants 2Health News:Study shows new strategy for developing antidepressants 3Health News:How to Spot, and Beat, the Holiday Blues 2Health News:FDA Reviewing Potential Anti-Arrhythmic Claims for Ranexa(R) 2Health News:FDA Reviewing Potential Anti-Arrhythmic Claims for Ranexa(R) 3Health News:BioHorizons Expands to New 44,000 Square Foot Facility 2
... acuity system allows you access to the ... The system includes 10 different optotypes, crowding ... animated characters. Random character sequencing eliminates memorization. ... single line and multiple line selection capability. ...
... Light Probes provide the surgeon with an ... interface to be easily visualized through the ... effect and light scatter technique, the surgeon ... deposits, flap edge folds, corneal flap striae ...
... visual acuity system allows you access to ... II. The system includes 10 different optotypes, ... and animated characters. Random character sequencing eliminates ... letter, single line and multiple line selection ...
... to 64 channel sleep diagnostic collection software. ... 64 channel sleep diagnostic collection software offers ... recording or post recording. The scoring displays ... sleep events including current number of events, ...
Medicine Products: